Yearly Archives: 2024
Here’s how Utah earned its No. 1 ranking for innovation
A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
Human Forms and Body Parts Trigger Strong Reactions in the Brain
Human Forms and Body Parts Trigger Strong Reactions in the Brain
Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology
Partnership aims to set new industry standards for managing mental health and cognitive conditions
SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS
SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS
BD Resolves Previously Disclosed SEC Investigation
BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.
NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD
VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]
Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)
LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.
CancerVax Targets Hard to Treat Pancreatic Cancer
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors
